Literature DB >> 33542414

A mutant α1antitrypsin in complex with heat shock proteins as the primary antigen in type 1 diabetes in silico investigation.

Paola Finotti1, Andrea Pagetta2.   

Abstract

Based on previous results demonstrating that complexes of a mutant α1-antitrypsin with the heat shock proteins (HSP)70 and glucose-regulated protein94 (Grp94) circulate in the blood of patients with type 1 diabetes, we raised the hypothesis that these complexes could represent the primary antigen capable of triggering the autoimmune reactions leading to overt diabetes. As a first approach to this issue, we searched whether A1AT and HSPs had a sequence similarity to major islet antigen proteins so as to identify among the similar sequences those with potential relevance for the pathogenesis of diabetes. A thorough in silico analysis was performed to establish the score of similarity of the human proteins: A1AT, pro-insulin (INS), GAD65, IAPP, IA-2, ICA69, Grp94, HSP70 and HSP60. The sequences of A1AT and HSPs with the highest score of similarity to the islet peptides reported in the literature as the main autoantigens in human diabetes were recorded. At variance with other HSPs, also including HSP90 and Grp78, Grp94 contained the highest number and the longest sequences with structural similarity to A1AT and to well-known immunogenic peptides/epitopes of INS, GAD65, and IA-2. The similarity of A1AT with Grp94 and that of Grp94 with INS also suggested a functional relationship among the proteins. Specific sequences were identified in A1AT, Grp94 and HSP70, with the highest score of cross-similarity to a pattern of eight different islet protein epitopes. The similarity also involved recently discovered autoantigens in type 1 diabetes such as a hybrid peptides of insulin and the defective ribosomal insulin gene product. The significant similarity displayed by specific sequences of Grp94 and A1AT to the islet peptides considered main antigens in human diabetes, is a strong indication for testing these sequences as new peptides of immunogenic relevance in diabetes.

Entities:  

Year:  2021        PMID: 33542414     DOI: 10.1038/s41598-021-82730-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  48 in total

1.  Expression of alpha-1 proteinase inhibitor in human islet microvascular endothelial cells.

Authors:  J Lou; F Triponez; J Oberholzer; H Wang; D Yu; L Buhler; N Cretin; G Mentha; C B Wollheim; P Morel
Journal:  Diabetes       Date:  1999-09       Impact factor: 9.461

2.  Expression and secretion of alpha1-proteinase inhibitor are regulated by proinflammatory cytokines in human pancreatic islet cells.

Authors:  Domenico Bosco; Paolo Meda; Philippe Morel; David Matthey-Doret; Dorothée Caille; Christian Toso; Leo H Bühler; Thierry Berney
Journal:  Diabetologia       Date:  2005-07-07       Impact factor: 10.122

Review 3.  Type 1 diabetes-early life origins and changing epidemiology.

Authors:  Jill M Norris; Randi K Johnson; Lars C Stene
Journal:  Lancet Diabetes Endocrinol       Date:  2020-01-27       Impact factor: 32.069

Review 4.  Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine.

Authors:  Bart O Roep; Daniel C S Wheeler; Mark Peakman
Journal:  Lancet Diabetes Endocrinol       Date:  2018-10-24       Impact factor: 32.069

Review 5.  The challenge of modulating β-cell autoimmunity in type 1 diabetes.

Authors:  Mark A Atkinson; Bart O Roep; Amanda Posgai; Daniel C S Wheeler; Mark Peakman
Journal:  Lancet Diabetes Endocrinol       Date:  2018-10-24       Impact factor: 32.069

Review 6.  Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process?

Authors:  Hubert Kolb; Matthias von Herrath
Journal:  Cell Metab       Date:  2016-11-10       Impact factor: 27.287

7.  Alpha 1-antitrypsin reduces inflammation and enhances mouse pancreatic islet transplant survival.

Authors:  Maria Koulmanda; Manoj Bhasin; Zhigang Fan; Dusan Hanidziar; Nipun Goel; Prabhakar Putheti; Babak Movahedi; Towia A Libermann; Terry B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

8.  Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase.

Authors:  Danny Jonigk; Mariam Al-Omari; Lavinia Maegel; Meike Müller; Nicole Izykowski; Jaewoo Hong; Kwangwon Hong; Soo-Hyun Kim; Martina Dorsch; Ravi Mahadeva; Florian Laenger; Hans Kreipe; Armin Braun; Galit Shahaf; Eli C Lewis; Tobias Welte; Charles A Dinarello; Sabina Janciauskiene
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-23       Impact factor: 11.205

9.  Exploration of α1-antitrypsin treatment protocol for islet transplantation: dosing plan and route of administration.

Authors:  Boris M Baranovski; Eyal Ozeri; Galit Shahaf; David E Ochayon; Ronen Schuster; Nofar Bahar; Noa Kalay; Pablo Cal; Mark I Mizrahi; Omer Nisim; Pnina Strauss; Eran Schenker; Eli C Lewis
Journal:  J Pharmacol Exp Ther       Date:  2016-11-07       Impact factor: 4.030

10.  Learning From Past Failures of Oral Insulin Trials.

Authors:  Aaron W Michels; Peter A Gottlieb
Journal:  Diabetes       Date:  2018-07       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.